GSK | pharmaphorum

Thursday 13 August 2026

GSK

News

Cambridge Biomedical Campus

GSK to quit Stevenage for new R&D site in Cambridge

In a major shake-up of its UK operations, GSK is building a brand new R&D centre in Cambridge and transfer operations there from its Stevenage campus.

News

J&J's oral IL-23 drug backed for psoriasis in EU

J&J's oral IL-23 drug backed for psoriasis in EU

J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.

News

Nuvalent buy delivers new cancer approval for GSK

Nuvalent buy delivers new cancer approval for GSK

GSK has its first approval from the $10.6bn takeover of Nuvalent, ROS1+ NSCLC therapy Jideytro, which becomes the company's first lung cancer product.

News

GSK abandons cough drug added in $2bn Bellus deal

GSK abandons cough drug added in $2bn Bellus deal

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning the programme.

News

No Plan B for Men B campaign

UK experts call for meningitis shots for all 15-year-olds

All 15-year-olds in the UK should be offered the meningitis B vaccine following the fatal outbreaks earlier this year, says the JCVI.

News

GSK to file Jemperli for rectal cancer after phase 3 readout

GSK to file Jemperli for rectal cancer after phase 3 readout

GSK's pivotal AZUR-1 trial of Jemperli monotherapy to delay or eliminate surgery in pre-operative rectal cancer has delivered a positive result.